Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter

RECENT NEWS

How Other Countries Freeload on U.S. Drug Research

How Other Countries Freeload on U.S. Drug Research

Letting Americans buy prescriptions from foreign retailers would impair the development of new cures....  Read more

Reduce drug prices by eliminating PBM rebates

Reduce drug prices by eliminating PBM rebates

Unless we end the rigged system of rebates, insurers, PBMs and drug companies will find themselves threatened with more g...  Read more

The Privacy Delusions Of Genetic Testing

The Privacy Delusions Of Genetic Testing

Genetic-testing companies cannot guarantee privacy. And many are actively selling user data to outside parties....  Read more

DRUGWONKS BLOG